[Health technology assessment in the field of rare diseases at Haute Autorité de Santé in France].
作者信息
Bélorgey Chantal
机构信息
Directrice de l'évaluation médicale, économique et de santé publique, Haute Autorité de Santé, 5, avenue du Stade de France, 93210 Saint-Denis, France.
出版信息
Med Sci (Paris). 2018 May;34 Hors série n°1:49-50. doi: 10.1051/medsci/201834s126. Epub 2018 Jun 18.
PMID:29911564
Abstract
摘要
相似文献
1
[Health technology assessment in the field of rare diseases at Haute Autorité de Santé in France].[法国高等卫生管理局在罕见病领域的卫生技术评估]
Med Sci (Paris). 2018 May;34 Hors série n°1:49-50. doi: 10.1051/medsci/201834s126. Epub 2018 Jun 18.
2
[France in the European cooperation for the technological evaluation of health products].[法国参与欧洲卫生产品技术评估合作项目]
Med Sci (Paris). 2018 May;34 Hors série n°1:57-59. doi: 10.1051/medsci/201834s130. Epub 2018 Jun 18.
3
[Not Available].[无可用内容]
Med Sci (Paris). 2016 Apr;32 Spec No 1:29-33. doi: 10.1051/medsci/201632s108. Epub 2016 May 2.
4
[Towards a better organisation of care for rare diseases in France : a ministry perspective].[迈向法国罕见病护理的更好组织：卫生部视角]
Med Sci (Paris). 2018 May;34 Hors série n°1:9-10. doi: 10.1051/medsci/201834s106. Epub 2018 Jun 18.
5
[Rare diseases: an "exceptional field of research. Interview by Catherine Holué].[罕见病：“一个特殊的研究领域”。凯瑟琳·霍吕访谈]
Rev Prat. 2012 Jan;62(1):89-90.
6
[Place of the expert patient in the assessments performed by the Haute Autorité de Santé].[专家患者在法国卫生高级管理局所进行评估中的地位]
Med Sci (Paris). 2018 May;34 Hors série n°1:30-31. doi: 10.1051/medsci/201834s115. Epub 2018 Jun 18.
7
Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?加拿大公共医疗体系下罕见病药物的报销情况：我们目前处于什么状况？
Healthc Policy. 2015 Aug;11(1):15-32.
8
Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.罕见（孤儿）病药物：一项关于税收激励措施的调查与提议
Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14.
9
[The stakes of pre- and post-market authorization development and clinical assessment].[上市前和上市后授权开发及临床评估的风险]
Presse Med. 2012 May;41 Suppl 1:S6-8. doi: 10.1016/j.lpm.2012.02.026. Epub 2012 Apr 6.
10
New modalities of prescription of ATUns: Evolutions and revolution.抗结核药物新的处方模式：演变与变革
Rev Neurol (Paris). 2020 May;176(4):290-292. doi: 10.1016/j.neurol.2019.07.023. Epub 2019 Oct 11.
Zotero 插件